Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).

Intercept Pharmaceuticals Inc. said the treatment obeticholic acid (OCA) showed an improvement in scarring on the organ in patients with a progressive fatty liver disease.